Colossal Biosciences: Funding, Investors & Team (Sep 2026)
Colossal creates disruptive technologies for extinct species restoration, critically endangered species protection and the repopulation of critical ecosystems that support the continuation of life on Earth. The company is the first to apply CRISPR technology for the purposes of species de-extinction, beginning with the woolly mammoth. Colossal is accepting humanity’s duty to restore Earth to a healthier state, while also solving for the future economies and biological necessities of the human condition through cutting-edge science and technologies.
Colossal Biosciences has raised $451M across 6 funding rounds on record, the most recent a Series C of $60.0M announced in Feb 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Colossal Biosciences Company Profile and Key Stats
Latest funding round on record: Feb 2026.
Colossal Biosciences Funding Rounds
1 of 6 rounds was announced without a disclosed amount and is excluded from the total.
Colossal Biosciences raised $60.0M in a Series A announced in Mar 2022.
7 months later, an undisclosed round was announced in Oct 2022 with no disclosed amount.
1.1 years later, an undisclosed round of $10.5M was announced in Nov 2023.
1.2 years later, a Series C of $200M was announced in Jan 2025.
8 months later, a Series C of $120M was announced in Sep 2025.
5 months later, a Series C of $60.0M was announced in Feb 2026.
Colossal Biosciences Founders and Leadership Team
Contact details for the Colossal Biosciences team: 2 of 3 have an email address on file.
Start 14-day free trial →Colossal Biosciences Funding Compared to Other Biotechnology Startups
Colossal Biosciences' latest round of $60.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Colossal Biosciences in Biotechnology and Dallas
Companies Similar to Colossal Biosciences
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Colossal Biosciences Funding FAQs
What does Colossal Biosciences do?
Colossal creates disruptive technologies for extinct species restoration, critically endangered species protection and the repopulation of critical ecosystems that support the continuation of life on Earth. The company is the first to apply CRISPR technology for the purposes of species de-extinction, beginning with the woolly mammoth. Colossal is accepting humanity’s duty to restore Earth to a healthier state, while also solving for the future economies and biological necessities of the human condition through cutting-edge science and technologies.
How much funding has Colossal Biosciences raised?
Colossal Biosciences has raised $451M across 6 rounds on record. The most recent is a Series C of $60.0M announced in Feb 2026.
When did Colossal Biosciences last raise funding?
Colossal Biosciences' most recent funding round on record is a Series C of $60.0M, announced in Feb 2026.
Who founded Colossal Biosciences?
FundedIQ lists George Church (Founder), Kent Wakeford (Founder) at Colossal Biosciences.
Who is the CEO of Colossal Biosciences?
Ben Lamm is listed as CEO at Colossal Biosciences.
Where is Colossal Biosciences headquartered?
Colossal Biosciences is based in Dallas, Texas, United States.
How many employees does Colossal Biosciences have?
Colossal Biosciences is in the 11-50 employee band.
How does Colossal Biosciences' funding compare to other Biotechnology startups?
Colossal Biosciences' latest round of $60.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Colossal Biosciences Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Colossal Biosciences is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.